Market research
ALSEN.PA Sensorion SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 142M
- P/E ratio
- Not available
- Analyst target
- 1.1375
- Dividend yield
- Not available
- Beta
- 0.42
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0012596468
- Market cap
- 142M
- P/E ratio
- Not available
- Analyst target
- 1.1375
- Dividend yield
- Not available
- Beta
- 0.42
About
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALSEN.PA discussion.
5 years, 5 months ago
Sensorion SA is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 73.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 73.0.
Finally, its free cash flow grew by 103.1% to $168K since the same quarter in the previous year.
Based on the above factors, Sensorion SA gets an overall score of 3/5.